Eiger BioPharmaceuticals, Inc.
Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives

Abstract:

In one aspect, methods of treating hyperinsulinemic hypoglycemia comprising administration of an effective amount of a derivative of an exendin-4 peptide are provided. In some embodiments, the method comprises subcutaneously administering to a patient having hyperinsulinemic hypoglycemia a therapeutically effective amount of exendin(5-39).